


GZNL-P36

Cat. No.:	HY-162484
Molecular Formula:	C ₂₉ H ₃₀ N ₄ O ₂
Molecular Weight:	466.57
Target:	SARS-CoV; Virus Protease
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL ^{Pro}), with an IC ₅₀ of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC ₅₀ range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C _{max} of 549 ng/mL, a half-life T _{1/2} of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse ^[1] .
IC ₅₀ & Target	IC ₅₀ : 6.45 nM (SARS-CoV-2 papain-like protease)

REFERENCES

[1]. Lu Y, et al., Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19[J]. bioRxiv, 2024: 2024.04. 03.587743.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA